Linagliptin

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).